Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Dr Andrew A. Parsons

Dr Andrew A. Parsons

Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS

Connect with Dr Andrew A. Parsons on LinkedIn
Website:

About the author:

Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.

He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.


Posts by Dr Andrew A. Parsons

Using Machine Learning for Identifying and Classifying Patient Groups

Posted on August 14th, 2017 in Pharma R&D

To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.

Continue reading “Using Machine Learning for Identifying and Classifying Patient Groups” »

The Eternal Triangle of Quality, Speed, and Cost

Posted on August 7th, 2017 in Pharma R&D

triangle-869123_640
A designer colleague once described to me the key issue involved in many of their creative design projects. It is finding the best balance between quality, speed, and cost. From a buyer perspective, we desire high quality, rapid delivery, and low cost. Continue reading “The Eternal Triangle of Quality, Speed, and Cost” »

Hopes, Issues, and Concerns in Tackling the Challenge of Dementia

Posted on July 24th, 2017 in Pharma R&D

With recent failures of large Phase 3 studies targeting the amyloid pathways, there is perhaps a need for some good news for scientists, clinicians, health services and the general public. Recently, there was some good news in the media. Continue reading “Hopes, Issues, and Concerns in Tackling the Challenge of Dementia” »

The certainty of uncertainty

Posted on July 17th, 2017 in Pharma R&D

The recent election results in France and the UK once again show that a week is a long time in politics. Who would have thought when the UK voted to Brexit that Emmanuel Macron would sweep into power following the creation of his new political party in April 2016? Continue reading “The certainty of uncertainty” »

  1. 1
  2. 2
  3. 3
  4. 6